1. Pharmacological action of ulinastatin

　　Ulinastatin is a refined glycoprotein extracted from human urine, which can inhibit trypsin and other trypsin, stabilize lysosomal membrane, inhibit the release of lysosomal enzyme, inhibit the production of myocardial MDF, and improve the circulation state in shock. Clinical and aprotinin double blind test confirmed that ulinastatin had obvious effect on various kinds of shock.

　　2. Pharmacokinetics of ulinastatin

　　After ulinastatin injection, the plasma concentration decreased rapidly, mainly in the kidney, liver and pancreas. It was eliminated from almost all tissues, with a biological half-life of about 24min and a half-life of about 40min. After 6h of administration, low molecular metabolites were excreted in urine, and excreted 24%. No accumulation was observed after continuous administration for 7 days.

　　3. Indications of ulinastatin

　　Acute pancreatitis (including acute pancreatitis after traumatic, postoperative and endoscopic retrograde cholangiopancreatography), acute worsening of chronic recurrent pancreatitis, acute circulatory failure (hemorrhagic shock, bacterial shock, traumatic shock, burn shock); It is also widely used in thoracic surgery, digestive surgery, tumor surgery, organ transplantation, organ resection and CPB surgery. This product is also used to treat and prevent renal dysfunction caused by tumor chemotherapy.

　　Above is the content of ulinastatin, if you want to know more, please continue to pay attention to Kangyuan company, we will be at your service.